Zobrazeno 1 - 10
of 190
pro vyhledávání: '"HANS-CHRISTIAN KOLBERG"'
Autor:
Philipp Ziegler, Andreas D. Hartkopf, Markus Wallwiener, Lothar Häberle, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Volkmar Müller, Laura L. Michel, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Hanna Huebner, Sabrina Uhrig, Lena A. Wurmthaler, Carolin C. Hack, Christoph Mundhenke, Christian Kurbacher, Peter A. Fasching, Rachel Wuerstlein, Michael Untch, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss, Chloë Goossens
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Although adequate physical activity has been shown to be beneficial in early breast cancer, evidence in metastatic breast cancer is sparse and contradictory, which could be related to distinct effects of physical activity on the d
Externí odkaz:
https://doaj.org/article/f6addaf5728b4463afe3407a59ff7008
Autor:
Peter A. Fasching, Chunling Hu, Steven N. Hart, Matthias Ruebner, Eric C. Polley, Rohan D. Gnanaolivu, Andreas D. Hartkopf, Hanna Huebner, Wolfgang Janni, Peyman Hadji, Hans Tesch, Sabrina Uhrig, Johannes Ettl, Michael P. Lux, Diana Lüftner, Markus Wallwiener, Lena A. Wurmthaler, Chloë Goossens, Volkmar Müller, Matthias W. Beckmann, Alexander Hein, Daniel Anetsberger, Erik Belleville, Pauline Wimberger, Michael Untch, Arif B. Ekici, Hans-Christian Kolberg, Arndt Hartmann, Florin-Andrei Taran, Tanja N. Fehm, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Lothar Häberle, Fergus J. Couch
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract Germline mutations in BRCA1 and BRCA2 (gBRCA1/2) are required for a PARP inhibitor therapy in patients with HER2-negative (HER2−) advanced breast cancer (aBC). However, little is known about the prognostic impact of gBRCA1/2 mutations in a
Externí odkaz:
https://doaj.org/article/7fc65e7d8ec9445caafcbb4945b9c522
Autor:
Stefanos Ioannis Moukas, Sabine Kasimir-Bauer, Mitra Tewes, Hans-Christian Kolberg, Oliver Hoffmann, Rainer Kimmig, Corinna Keup
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-17 (2023)
Abstract Biomarkers to identify metastatic breast cancer (mBC) patients resistant to CDK4/6 inhibition (CDK4/6i) are currently missing. We evaluated the usefulness of the monocyte-to-lymphocyte ratio (MLR), the neutrophil–to-lymphocyte ratio (NLR)
Externí odkaz:
https://doaj.org/article/b8426ff79ebb4e70beea6ba3dead165e
Autor:
Hans-Christian Kolberg, Christian Jackisch, Sara A. Hurvitz, Julie Winstone, Helen Barham, Vladimir Hanes, Delphine Courmier
Publikováno v:
Breast, Vol 57, Iss , Pp 95-103 (2021)
Trastuzumab, a key treatment for HER2-positive breast cancer, is available in weight-based IV and fixed-dose (600 mg) SC formulations. While the Phase 3 HannaH trial indicated non-inferiority of the SC formulation, there is some concern that the targ
Externí odkaz:
https://doaj.org/article/e21278273a18447ca4d6abf465169331
Autor:
Corinna Keup, Vinay Suryaprakash, Siegfried Hauch, Markus Storbeck, Peter Hahn, Markus Sprenger-Haussels, Hans-Christian Kolberg, Mitra Tewes, Oliver Hoffmann, Rainer Kimmig, Sabine Kasimir-Bauer
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-14 (2021)
Abstract Background Single liquid biopsy analytes (LBAs) have been utilized for therapy selection in metastatic breast cancer (MBC). We performed integrative statistical analyses to examine the clinical relevance of using multiple LBAs: matched circu
Externí odkaz:
https://doaj.org/article/39103299acfb493b841699ff8cdd9777
Autor:
Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Johannes Ettl
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. Howe
Externí odkaz:
https://doaj.org/article/3595f6bd2f1948ae89b5ca12ff495d0f
Autor:
Markus Wallwiener, Naiba Nabieva, Manuel Feisst, Tanja Fehm, Johann de Waal, Mahdi Rezai, Bernd Baier, Gerold Baake, Hans-Christian Kolberg, Martin Guggenberger, Mathias Warm, Nadia Harbeck, Rachel Wuerstlein, Jörg-Uwe Deuker, Peter Dall, Barbara Richter, Grischa Wachsmann, Cosima Brucker, Jan Willem Siebers, Milos Popovic, Thomas Kuhn, Christopher Wolf, Hans-Walter Vollert, Georg-Peter Breitbach, Wolfgang Janni, Robert Landthaler, Andreas Kohls, Daniela Rezek, Thomas Noesselt, Gunnar Fischer, Stephan Henschen, Thomas Praetz, Volker Heyl, Thorsten Kühn, Thomas Krauss, Christoph Thomssen, Andre Hohn, Hans Tesch, Christoph Mundhenke, Alexander Hein, Claudia Rauh, Christian M. Bayer, Katja Schmidt, Erik Belleville, Sara Y. Brucker, Peyman Hadji, Matthias W. Beckmann, Diethelm Wallwiener, Sherko Kümmel, Andreas Hartkopf, Peter A. Fasching
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative
Externí odkaz:
https://doaj.org/article/288dc4797ece43779ee02ebaad868ad3
Autor:
Carolin C. Hack MD, Peter A. Fasching MD, Tanja Fehm MD, Johann de Waal MD, Mahdi Rezai MD, Bernd Baier MD, Gerold Baake MD, Hans-Christian Kolberg MD, Martin Guggenberger MD, Mathias Warm MD, Nadia Harbeck MD, Rachel Wuerstlein MD, Jörg-Uwe Deuker MD, Peter Dall MD, Barbara Richter MD, Grischa Wachsmann MD, Cosima Brucker MD, Jan W. Siebers MD, Nikos Fersis MD, Thomas Kuhn MD, Christopher Wolf MD, Hans-Walter Vollert MD, Georg-Peter Breitbach MD, Wolfgang Janni MD, Robert Landthaler MD, Andreas Kohls MD, Daniela Rezek MD, Thomas Noesslet MD, Gunnar Fischer MD, Stefan Henschen MD, Thomas Praetz MD, Volker Heyl MD, Thorsten Kühn MD, Thomas Krauss MD, Christoph Thomssen MD, Andre Hohn MD, Hans Tesch MD, Christoph Mundhenke MD, Alexander Hein MD, Claudia Rauh MD, Christian M. Bayer MD, Adib Jacob, Katja Schmidt PhD, Erik Belleville PhD, Peyman Hadji MD, Sara Y. Brucker MD, Diethelm Wallwiener MD, Sherko Kümmel MD, Matthias W. Beckmann MD, Daniela Paepke MD
Publikováno v:
Integrative Cancer Therapies, Vol 16 (2017)
Background . Breast cancer patients often use complementary and alternative medicine, but few prospectively collected data on the topic are available specifically for postmenopausal breast cancer patients. A large prospective study was therefore cond
Externí odkaz:
https://doaj.org/article/d2a81d21043643fba118f1259ec81715
Autor:
Peter A. Fasching, Alexander Hein, Hans-Christian Kolberg, Lothar Häberle, Sabrina Uhrig, Matthias Rübner, Erik Belleville, Carolin C. Hack, Tanja N. Fehm, Wolfang Janni, Arndt Hartmann, Ramona Erber, Anna-Katharin Theuser, Sara Y. Brucker, Andreas D. Hartkopf, Michael Untch
Publikováno v:
European Journal of Cancer. 184:1-9
Autor:
Hans-Christian Kolberg, Helena Niesing, Jayant S Vaidya, Leyla Akpolat-Basci, Abdrhman Maguz, Oliver Hoffmann, György Lövey, Miltiades Stephanou, Cornelia Kolberg-Liedtke
Publikováno v:
Cancer Research. 83:P1-09
Background: Mastectomy is the treatment recommended by most national and international guidelines for in-breast-recurrence of breast cancer after breast conserving surgery (BCS) and external beam radiation therapy (EBRT). In selected cases it is poss